Brain

Prime Biome Reviews And Complaints: A Detailed Study Released That’s Needs to Be Adopted for Which Type of Peoples?

ST. PETERSBURG, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- This is a comprehensive examination of the groundbreaking research behind Prime…

10 months ago

Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD

BOSTON, March 11, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science…

10 months ago

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025  EDEN PRAIRIE, Minn., March…

10 months ago

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development…

10 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer…

10 months ago

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701…

10 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as…

10 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…

10 months ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM…

10 months ago

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year…

10 months ago